- 24D2 (See other available formats)
- Regulatory Status
- Other Names
- HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, oncogene NGL, neuroblastoma- or glioblastoma-derived, HER-2
- Mouse IgG1, κ
- Ave. Rating
- Submit a Review
- Product Citations
CD340 is also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. It is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain and has an approximate molecular weight of 185 kD. CD340 contains three furin repeats and two cheY homologous receiver domains in the extracellular region (ECR). The HER2/erbB2 protein is expressed on many tumor cells, including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow mesenchymal stem cells. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression; this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Overexpression of erbB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphorylation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).Product Details
- Antibody Type
- Host Species
- NIH-3T3 transfected with human HER-2
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
- Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet™.
This product is subject to proprietary rights of Becton, Dickinson and Company and its affiliates. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. patent(s), pending patent applications and/or foreign equivalents.
- Excitation Laser
Violet Laser (405 nm)
(PubMed link indicates BioLegend citation)
- Bühring HJ, et al. 1995. Blood 86:1916.
- Product Citations
AB_2563990 (BioLegend Cat. No. 324420)
- Member of the epidermal growth factor receptor family of cell membrane tyrosine kinases. Single transmembrane pass protein with an approximate molecular weight of 185 kD. Contains three furin repeats and two cheY homologous receiver domains in the ECR.
Expressed on many tumor cells including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow MSCs.
- Contains no ligand binding domain and interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. Involved in embryonic development and cancer progression.
- CD340 (HER2/erbB2) interacts with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others.
- Extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).
- Cell Type
- Biology Area
- Cell Biology, Immunology, Neuroscience, Synaptic Biology
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
1. Akiyama T, et al. 1986. Science 232:1644.
2. Bargmann CI, et al. 1986. Nature 319:226.
3. Pegram MD, et al. 1997. Oncogene 15:537.
4. Slamon DJ, et al. 1989. Science 244:707.
5. Leone F, et al. 2003. J. Leukocyte Biol. 74:593.
- Gene ID
- 2064 View all products for this Gene ID
- View information about CD340 on UniProt.org
- What is the F/P ratio range of our BV421™ format antibody reagents?
It is lot-specific. On average it ranges between 2-4.
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.